company background image
SAR

Sareum Holdings AIM:SAR Stock Report

Last Price

UK£1.25

Market Cap

UK£85.1m

7D

19.0%

1Y

-33.3%

Updated

08 Feb, 2023

Data

Company Financials +

SAR Stock Overview

Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases.

SAR fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

New

Notes are coming soon

Sareum Holdings plc Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Sareum Holdings
Historical stock prices
Current Share PriceUK£1.25
52 Week HighUK£3.45
52 Week LowUK£0.55
Beta-0.53
1 Month Change16.28%
3 Month Change38.89%
1 Year Change-33.33%
3 Year Change566.67%
5 Year Change177.78%
Change since IPO-16.67%

Recent News & Updates

Sareum Holdings (LON:SAR) Is In A Good Position To Deliver On Growth Plans

Aug 06
Sareum Holdings (LON:SAR) Is In A Good Position To Deliver On Growth Plans

Recent updates

Sareum Holdings (LON:SAR) Is In A Good Position To Deliver On Growth Plans

Aug 06
Sareum Holdings (LON:SAR) Is In A Good Position To Deliver On Growth Plans

We Think Sareum Holdings (LON:SAR) Can Afford To Drive Business Growth

Apr 22
We Think Sareum Holdings (LON:SAR) Can Afford To Drive Business Growth

Sareum Holdings (LON:SAR) Is In A Good Position To Deliver On Growth Plans

Jan 06
Sareum Holdings (LON:SAR) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Sareum Holdings' (LON:SAR) Cash Burn Rate

Aug 31
We're Not Very Worried About Sareum Holdings' (LON:SAR) Cash Burn Rate

We're Hopeful That Sareum Holdings (LON:SAR) Will Use Its Cash Wisely

May 07
We're Hopeful That Sareum Holdings (LON:SAR) Will Use Its Cash Wisely

What Type Of Shareholders Own The Most Number of Sareum Holdings plc (LON:SAR) Shares?

Dec 23
What Type Of Shareholders Own The Most Number of Sareum Holdings plc (LON:SAR) Shares?

Shareholder Returns

SARGB PharmaceuticalsGB Market
7D19.0%3.4%1.4%
1Y-33.3%4.4%-5.6%

Return vs Industry: SAR underperformed the UK Pharmaceuticals industry which returned 4.4% over the past year.

Return vs Market: SAR underperformed the UK Market which returned -5.6% over the past year.

Price Volatility

Is SAR's price volatile compared to industry and market?
SAR volatility
SAR Average Weekly Movement16.0%
Pharmaceuticals Industry Average Movement6.7%
Market Average Movement5.1%
10% most volatile stocks in GB Market11.1%
10% least volatile stocks in GB Market2.6%

Stable Share Price: SAR is more volatile than 90% of UK stocks over the past 3 months, typically moving +/- 16% a week.

Volatility Over Time: SAR's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of UK stocks.

About the Company

FoundedEmployeesCEOWebsite
20035Tim Mitchellhttps://www.sareum.com

Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. It develops small molecule therapeutic drugs based on its Sareum Kinase Inhibitor Library drug discovery platform. The company’s product pipeline includes TYK2/JAK1 kinase, which is in preclinical stage; Checkpoint Kinase 1, which has completed clinical phase II; and FLT3+Aurora kinase, which is in preclinical stage.

Sareum Holdings plc Fundamentals Summary

How do Sareum Holdings's earnings and revenue compare to its market cap?
SAR fundamental statistics
Market CapUK£85.09m
Earnings (TTM)-UK£2.17m
Revenue (TTM)n/a

0.0x

P/S Ratio

-39.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SAR income statement (TTM)
RevenueUK£0
Cost of RevenueUK£0
Gross ProfitUK£0
Other ExpensesUK£2.17m
Earnings-UK£2.17m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.032
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did SAR perform over the long term?

See historical performance and comparison